BioDetego is developing the next generation of cancer diagnostics - identifying who needs chemotherapy better than traditional staging or molecular diagnostics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded June 2012
  • Employees 0
  • Incorporation Type LLC
  • Website

Company Summary

Existing colon cancer diagnostics provide no individualized data that identifies patients that are likely to relapse. Our test platform accurately determines patients' risk of relapse, provides 100% actionable information to guide treatment decisions, and can be developed for any cancer type. The test platform will offer payors savings by reducing undertreatment of patients in need of chemotherapy and harmful overtreatment of low risk patients.


  • Photo
    Co-founder, CEO

    Dr. Zuzga is a research scientist and entrepreneur. His research identified “driver” metastasis biomarkers that are associated with cancer progression and this work serves as the foundation of BioDetego’s platform technology

  • 9abd80a8 9dba 4384 b98a 26d2e4435833
    Executive Chair

    Mr. Shuber co-founded Exact Sciences and developed the first non-invasive diagnostic test for CRC screening. Later he co-founded Predictive Biosciences and developed the first diagnostic combining protein and DNA. He has over 100 issued and pending patent applications.


  • 7f4fa440 f9d7 4a5f 800d 737f4e9da8f1
    Business Advisor
    Default avatar
    Nicholas Siciliano
    Business Advisor
    Default avatar
    Massimo Cristofanilli, M.D., FACP
    Clinical Advisory Board
  • 99964e65 dd5a 4d64 be7b 7f19456a353c
    Clinical Advisory Board
    Default avatar
    GianMario Pitari, M.D., Ph.D.

Previous Investors

  • Default avatar
    Ben Franklin Technology Partners
    Default avatar